MAPT and Alzheimer disease: In AD mice at an age with evident plaque deposition, TREM2 enhancement with an agonist antibody significantly exacerbated tau pathology after brain injection of human-derived aggregated tau, without effects on plaque burden (Jain et al., 2023).